Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00985699
First received: September 25, 2009
Last updated: March 5, 2011
Last verified: September 2009
  Purpose

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at genes in tissue samples from patients with B-cell non-Hodgkin lymphoma.


Condition Intervention
Lymphoma
Genetic: polymorphism analysis
Other: laboratory biomarker analysis
Other: pharmacogenomic studies

Study Type: Observational
Official Title: Pharmacogenomics of Oxidative Stress-Related Genes in Lymphoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Association of polymorphisms in oxidative stress-related genes with overall survival and/or progression-free survival [ Designated as safety issue: No ]
  • Association of polymorphisms in these genes with rate of grade 4-5 hematologic toxicity [ Designated as safety issue: No ]

Estimated Enrollment: 670
Study Start Date: April 2009
Detailed Description:

OBJECTIVES:

  • To determine if toxicity following treatment for lymphoma varies according to genetic polymorphisms in oxidative stress-related genes (i.e., SOD2, CAT, GPX1, GSTM1, and GSTP1).
  • To assess whether these genetic polymorphisms are associated with progression-free survival and/or overall survival in these patients treated for lymphoma.

OUTLINE: Previously collected samples are used for biomarker analysis.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of aggressive B-cell non-Hodgkin lymphoma

    • Previously treated with curative intent using anthracycline-based therapies
  • Previously collected paraffin-embedded diagnostic tissues from clinical trials that were collected as part of SWOG treatment protocols (S8516, S8736, S9125, S9240, and S9349) available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00985699

Sponsors and Collaborators
Southwest Oncology Group
Investigators
Study Chair: Margaret M. Briehl, PhD University of Arizona
  More Information

Additional Information:
No publications provided

Responsible Party: Laurence H. Baker, Southwest Oncology Group - Group Chair's Office
ClinicalTrials.gov Identifier: NCT00985699     History of Changes
Other Study ID Numbers: CDR0000643248, SWOG-S8516-S8736-S9125-S9240-S
Study First Received: September 25, 2009
Last Updated: March 5, 2011
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
non-Hodgkin lymphoma
cutaneous B-cell non-Hodgkin lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on July 20, 2014